Business Wire

CA-GILEAD-SCIENCES

Share
Gilead Sciences Announces Changes to Senior Leadership Team

Gilead Sciences, Inc. (Nasdaq: GILD) announced today changes to the company’s senior leadership team. Gregg Alton, Chief Patient Officer, and Katie Watson, Executive Vice President, Human Resources, will be departing Gilead. Jyoti Mehra has been named Executive Vice President, Human Resources, and will assume responsibility for the worldwide HR function.

Mr. Alton joined Gilead in 1999 and most recently has led Gilead’s corporate and medical affairs functions and developing world access programs, as well as commercial operations in certain countries of Asia and Latin America. He previously served as general counsel and helped to architect the company’s innovative access model for HIV and viral hepatitis medicines in resource-limited countries. He will remain with Gilead through October 4 and plans to serve in an advisory capacity until the end of the year to help transition his responsibilities to other parts of the organization.

“Gregg has been a valued leader at Gilead for nearly 20 years,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead. “His unwavering focus on enabling and expanding access to medicines has allowed the company to help millions of individuals in countries most heavily impacted by HIV, hepatitis B and hepatitis C. I want to thank Gregg for his many contributions and tireless advocacy.”

“I am honored to have had the opportunity to help lead Gilead for nearly two decades,” said Mr. Alton. “On behalf of the organizations I have had a chance to lead, I am extraordinarily proud of the work we have done together to drive innovative solutions to reach the people most in need of our medications around the world.”

Ms. Watson joined Gilead in 2003 and during her 16 years with the company has helped to support significant organizational growth around the world. She has been responsible for attracting, developing and retaining talent, and delivering a strategic approach to engaging the company’s employees. She has helped to foster a culture that builds on Gilead’s core values of inclusion, teamwork, excellence, accountability and integrity.

“Katie has had a tremendous impact on Gilead, and I would like to thank her for her many contributions, including her dedication to improving the experience for the more than 11,000 employees at our company,” commented Mr. O’Day. “It is a testament to her leadership and her skill in developing people that we were quickly able to identify a strong successor. I know Jyoti will build on the important work underway to ensure Gilead is considered among the best places to work in our industry.”

“Helping Gilead grow and hire so many talented individuals and working to develop and retain our employees has been a privilege for the past 16 years,” commented Ms. Watson. “I am deeply appreciative of the opportunity to be a part of a company that has transformed care for patients, and I am confident our HR organization will continue contributing to this mission.”

Effective August 5, Ms. Mehra will be appointed as Ms. Watson’s successor. Ms. Watson will depart Gilead on September 1, remaining with Gilead in an advisory capacity through the end of the year to ensure a smooth transition. Ms. Mehra joined Gilead in 2017 as Vice President, Human Resources. She has more than 20 years of experience building organizational capabilities and shaping high-performing teams and cultures. She has worked across the United States, Europe and Asia. Prior to joining Gilead, she held positions of increasing seniority at Novartis Pharmaceuticals Corp. and Eli Lilly & Co.

“It is a great privilege to take on this role and to lead Gilead’s Human Resources organization,” said Ms. Mehra. “As a company, Gilead has enjoyed tremendous success because of the smart and talented people who work here. It is truly an honor to have the opportunity to continue to shape Gilead’s culture in this position and to build on the company’s strong past by adding organizational capabilities.”

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information about Gilead, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1 800-GILEAD-5 or 1-650-574-3000.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release

Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release

IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye